newsfilter
← Latest News
GlobeNewswire·

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

CAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced positive results from a preclinical study on